Clearside Biomedical reports Q4 net loss of $9.7M; Phase 2b wet AMD trial on track for Q2 2023

Clearside Biomedical, Inc.

Q4 net loss $9.7M ($0.16/share) vs net income $18.7M ($0.31/share) in Q4 2021 on lower license revenue.
Full-year 2022 net loss $32.9M ($0.55/share) vs net income $376K ($0.01/share) in 2021.
Cash $48.3M at Dec 31, 2022; runway into Q2 2024.
Phase 2b ODYSSEY trial of CLS-AX in wet AMD to start Q2 2023; comparator arm adjusted to on-label aflibercept per FDA draft guidance.
Bausch + Lomb trained over 1,000 retinal physicians on SCS Microinjector for XIPERE.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Clearside Biomedical, Inc. reported Year ended December 31, 2022 results: revenue $1.3 million, net income Net loss of $32.9 million, EPS $0.55 per share.

Period: Year ended December 31, 2022
Revenue: $1.3 million
Net income: Net loss of $32.9 million
EPS: $0.55 per share
Result: reported results

Exact text from the filing

Clearside’s license and other revenue for the year ended December 31, 2022, was $1.3 million, compared to $29.6 million for the year ended December 31, 2021. The $28.2 million decrease was primarily attributable to one-time milestone payments received from XIPERE licensing partners in 2021. Cost of goods sold for the year ended December 31, 2022, was $204,000, compared to $0 for the year ended December 31, 2021. This increase was related to sales of Clearside’s SCS Microinjector. Research and development expenses for the year ended December 31, 2022, were $19.6 million, compared to $18.5 million for the year ended December 31, 2021. The $1.1 million increase was primarily attributable to CLS-AX program costs. General and administrative expenses for the year ended December 31, 2022, were $11.8 million, compared to $11.7 million for the year ended December 31, 2021. Net loss for the year ended December 31, 2022, was $32.9 million, or $0.55 per share of common stock, compared to net incom

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Clearside Biomedical, Inc. reported Fourth quarter 2022 results: revenue $330,000, net income Net loss of $9.7 million, EPS $0.16 per share.

Period: Fourth quarter 2022
Revenue: $330,000
Net income: Net loss of $9.7 million
EPS: $0.16 per share
Result: reported results

Exact text from the filing

Clearside’s license and other revenue for the fourth quarter of 2022 was $330,000, compared to $25.7 million for the fourth quarter of 2021. The $25.4 million decrease was primarily attributable to one-time milestone payments received from XIPERE licensing partners in the fourth quarter of 2021. Cost of goods sold for the fourth quarter of 2022 was $204,000, compared to $0 for the fourth quarter of 2021. This increase was related to sales of Clearside’s SCS Microinjector. Research and development expenses for the fourth quarter of 2022 were $5.0 million, compared to $3.8 million for the fourth quarter of 2021. The $1.2 million increase was primarily attributable to preclinical research program costs. General and administrative expenses for the fourth quarter of 2022 were $3.2 million, compared to $3.1 million for the fourth quarter of 2021. Net loss for the fourth quarter of 2022 was $9.7 million, or $0.16 per share of common stock, compared to net income of $18.7 million, or $0.31 per

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.